Verrucous carcinoma of oral cavity

Summary

Verrucous carcinoma of oral cavity (MONDO:0021538) is a cancer and 54 clinical trials. Top therapeutic interventions include cisplatin, sorafenib, and lapatinib. A subtype of oral cavity squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 54

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	verrucous carcinoma of oral cavity
Mondo ID	MONDO:0021538
NCIT	C8174
SNOMED CT	403889000
UMLS	C0280306
MedGen	124716
GARD	0025335
Anatomy (UBERON)	UBERON:0000167
Is cancer (heuristic)	yes

Also known as: mouth verrucous carcinoma · oral cavity verrucous cancer · oral cavity verrucous carcinoma · verrucous carcinoma of mouth · verrucous carcinoma of the mouth · verrucous carcinoma of the oral cavity

Disease family

This is a subtype of oral cavity squamous cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › head and neck carcinoma › head and neck squamous cell carcinoma › lip and oral cavity squamous cell carcinoma › oral cavity squamous cell carcinoma › verrucous carcinoma of oral cavity

Related subtypes (6): tongue squamous cell carcinoma, maxillary sinus squamous cell carcinoma, squamous cell carcinoma of lip, squamous cell carcinoma of floor of mouth, squamous cell carcinoma of buccal mucosa, salivary gland squamous cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 54.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	22
PHASE1	18
Not specified	10
PHASE1/PHASE2	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00588770	PHASE3	ACTIVE_NOT_RECRUITING	Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT02734537	PHASE2	RECRUITING	Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT00033618	PHASE2	COMPLETED	Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
NCT00095628	PHASE2	COMPLETED	SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00096512	PHASE2	COMPLETED	S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00101348	PHASE1/PHASE2	COMPLETED	Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
NCT00103259	PHASE2	COMPLETED	Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT00114283	PHASE2	COMPLETED	Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
NCT00458978	PHASE2	COMPLETED	Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
NCT00492089	PHASE2	COMPLETED	Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
NCT00507767	PHASE2	COMPLETED	Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00513435	PHASE2	COMPLETED	Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00939627	PHASE2	COMPLETED	Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
NCT01044433	PHASE2	COMPLETED	Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
NCT01192815	PHASE2	TERMINATED	Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
NCT01256385	PHASE2	COMPLETED	Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
NCT01316757	PHASE2	COMPLETED	Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
NCT01414426	PHASE2	COMPLETED	Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
NCT01469429	PHASE1/PHASE2	COMPLETED	Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
NCT01674374	PHASE2	WITHDRAWN	Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy
NCT01816984	PHASE1/PHASE2	COMPLETED	PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT02007200	PHASE2	COMPLETED	Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
NCT02068157	PHASE2	TERMINATED	Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
NCT02119728	PHASE2	WITHDRAWN	Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity
NCT02123511	PHASE2	COMPLETED	Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
NCT02196168	PHASE2	TERMINATED	Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00023959	PHASE1	COMPLETED	Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
NCT00030498	PHASE1	COMPLETED	Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
NCT00031681	PHASE1	COMPLETED	7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
NCT00049283	PHASE1	COMPLETED	Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
NCT00089362	PHASE1	COMPLETED	Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00397384	PHASE1	COMPLETED	Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
NCT00470496	PHASE1	COMPLETED	Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
NCT00906360	PHASE1	TERMINATED	Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
NCT01249443	PHASE1	TERMINATED	Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
NCT01254617	PHASE1	COMPLETED	Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
NCT01283178	PHASE1	TERMINATED	Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC
NCT01332279	PHASE1	WITHDRAWN	Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
NCT01334177	PHASE1	COMPLETED	TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
NCT01528137	PHASE1	TERMINATED	Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	6
SORAFENIB	4	4
LAPATINIB	4	3
DASATINIB ANHYDROUS	4	2
ERLOTINIB HYDROCHLORIDE	4	1
IXABEPILONE	4	1
PORFIMER SODIUM	4	1
TEMSIROLIMUS	4	1
VANDETANIB	4	1
CEDIRANIB MALEATE	3	1
SARACATINIB	3	1
TALACTOFERRIN ALFA	3	1
HPPH	2	2
ISPINESIB	2	1
SOY ISOFLAVONES	2	1
UCN-01	2	1
ALVESPIMYCIN HYDROCHLORIDE	1	1
CHEMBL2326523	0	1
CHEMBL4583196	0	1
CHEMBL4438584	0	1
CHEMBL1236539	0	1